uPath PD-L1 (SP263) image analysis, NSCLC
Use left and right arrow keys to scroll between the tabs
uPath whole slide image analysis algorithms
An intelligent and advanced digital pathology solution requires artificial intelligence-based image analysis tools that empower pathologists to confidently and objectively assess whole tissue slide images.
The uPath PD-L1 (SP263) image analysis, NSCLC algorithm* is an adjunctive computer-assisted tool that identifies PD-L1 positive and negative tumor cells within a pathologist-annotated viable tumor region in images of formalin-fixed, paraffin-embedded Non-small cell lung cancer (NSCLC) tissue.
A robust and reliable solution for enhanced image analysis
Integrated and ready-to-use
Validated for use with the VENTANA PD-L1 (SP263) assay and navify® Digital Pathology.
Quick and automated
Pathologist-trained image analysis algorithm quickly calculates PD-L1 tumor cell positivity.
Accurate, consistent and confident
Actionable assessment of slide images that are objective and reproducible.1,2,3,4
Enhancing your pathology workflow
- Enhanced accuracy with a Pathologist-trained image analysis algorithm which results in objective and reproducible scoring of slide images scanned on VENTANA DP 200 or VENTANA DP 600 slide scanner and stained with the VENTANA PD-L1 (SP263) Assay1,2,3,4
- Fully embedded into the Roche uPath enterprise software/ navify Digital Pathology to enable seamless viewing, aligning, syncing, sharing, and reporting
- Speed up time to results for user-defined regions of interest with whole slide analysis (WSA) and automated pre-computing of the slide image prior to pathologist assessment
- Quickly calculate PD-L1 tumor cell positivity
- A clear visual overlay highlights tumor cells with and without membranous staining for easy reference
Specifications
| Scanner | VENTANA DP 200 and VENTANA DP 600 slide scanners |
| Software | navify Digital Pathology |
| Algorithm | uPath PD-L1 (SP263) image analysis, NSCLC* |
| Assay | Ventana PD-L1 (SP263) Assay |
| Tissue Type | NSCLC |
| Scoring | TC+ |
| Regulatory status | Research Use Only (RUO) |
Maximize the potential of your digital pathology laboratory
The Roche Digital Pathology solution comprises high-performance hardware, software and uPath whole slide image analysis algorithms, and works in integrated harmony with the full Roche diagnostic portfolio for an end-to-end experience that enhances pathology workflows.
*For research use only. Not for use in diagnostic procedures.
Roche Digital Pathology Dx, including navify Digital Pathology, is intended for specific clinical applications and is for research and educational use for other applications. Please review the product labeling for compliance before utilization.
NAVIFY and VENTANA and UPATH are trademarks of Roche. Other product names and trademarks are the property of their respective owners.
References:
- García-Porrero , G. et al. (2022). Mod Pathol 35, 318–401. (Abstract # 240).
- Haragan, A., et al. (2021). J Thorac Oncol 16.3, S161-S162. . (Abstract # MA08.05).
- Miri, MS., et al. (2020). Mod Pathol 33, 1604–1669. (Abstract #1572).
- Miri, MS, et al, (2021). Virchows Arch 479, 1–320. (Abstract # PS-14-003).
